Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art

References

• Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H. 2009. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual targeting approach in a murine solid tumor model. J Control Release. 137:8–14.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Katare OP, Vyas SP. 2001. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 228:43–52.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B. 2002. A novel liposomal formulation of dithranol for psoriasis: preliminary results. J Dermatol. 29:529–532.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Amin S, Rahman M, Rub RA, Singhal M, Ahmad MZ, et al. 2015. Solid matrix based lipidic nanoparticles in oral cancer chemotherapy: applications and pharmacokinetics. Curr Drug Metab. 16:633–644.
   PubMed Web of Science ®Google Scholar
• Akhter S, Ahmad I, Ahmad MZ, Ramazani F, Singh A, Rahman Z, et al. 2013. Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets. 13:362–378.
   PubMed Web of Science ®Google Scholar
• Akhter S, Ahmad MZ, Ahmad FJ, Storm G, Kok RJ. 2012. Gold nanoparticles in theranostic oncology: current state-of-the-art. Expert Opin Drug Deliv. 9:1225–1243.
   PubMed Web of Science ®Google Scholar
• Akhter S, Ahmad Z, Singh A, Ahmad I, Rahman M, Anwar M, et al. 2011. Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern. Curr Pharm Des. 17:1834–1850.
   PubMed Web of Science ®Google Scholar
• Akira I, Yuko K, Hiroyuki H, Kikkawa H, Horiuchi A, Watanabe Y, Kobayashi T. 2004. Magnetite nanoparticle-loaded anti-HER2 in nunoliposome for combination of antibody therapy with hyperthermia. Cancer Lett. 212:167–175.
   PubMed Web of Science ®Google Scholar
• Ali MF, Salah M, Rafea M. 2008. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit. 12:I66–I74.
   Google Scholar
• Alving CR, Kinsky SC, Haxby JA, Kinsky CB. 1969. Antibody binding and complement fixation by a liposomal model membrane. Biochemistry. 8:1582–1587.
   PubMed Web of Science ®Google Scholar
• Bangham AD, Horne RW. 1964. Negative staining of phospholipids and their structural modification by surface active agents as observed in the electron microscope. J Mol Biol. 8:660–668.
   PubMed Web of Science ®Google Scholar
• Bangham AD, Standish MM, Watkins JC. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 13:238–252.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. 2012. Doxil® – the first FDA-approved nano-drug: lessons learned. J Control Release. 160:117–134.
   PubMed Web of Science ®Google Scholar
• Bhatia A, Kumar R, Katare OP. 2004. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. J Pharm Pharm Sci. 7:252–259.
   PubMed Web of Science ®Google Scholar
• Bhatia A, Singh B, Wadhwa S, Raza K, Katare OP. 2014. Novel phospholipid-based topical formulations of tamoxifen: evaluation for antipsoriatic activity using mouse-tail model. Pharm Dev Technol. 19:160–163.
   PubMed Web of Science ®Google Scholar
• Bonanomi MH, Velvart M, Stimpel M, Roos KM, Fehr K, Weder HG. 1987. Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis. Rheumatol Int. 7:203–212.
   PubMed Web of Science ®Google Scholar
• Carter P, Smith L, Ryan M. 2004. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer. 11:659–687.
   PubMed Web of Science ®Google Scholar
• Chiu SJ, Liu S, Perrotti D, Marcucci G, Lee RJ. 2006. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release. 112:199–207.
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Chen ZG, Shin DM. 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 14:1310–1316.
   PubMed Web of Science ®Google Scholar
• Cleland LG, Shandling M, Percy JS, Poznansky MJ. 1979. Liposomes: a new approach to gold therapy? J Rheumatol Suppl. 5:154–163.
   PubMedGoogle Scholar
• Corvo ML, Boerman OC, Oyen WJ, Jorge JC, Cruz ME, Crommelin DJ, Storm G. 2000. Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharm Res. 17:600–606.
   PubMed Web of Science ®Google Scholar
• Cotran RS, Majno G. 1964. The delayed and prolonged vascular leakage in inflammation. I. Topography of the leaking vessels after thermal injury. Am J Pathol. 45:261–281.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature. 420:860–867.
   PubMed Web of Science ®Google Scholar
• Cruz ME, Manuela Gaspar M, Barbara M, Martins F, Corvo ML. 2005. Liposomal superoxide dismutases and their use in the treatment of experimental arthritis. Methods Enzymol. 391:395–413.
   PubMed Web of Science ®Google Scholar
• Dass CR. 2002. Liposome-mediated delivery of oligodeoxynucleotides in vivo. Drug Deliv. 9:169–180.
   PubMed Web of Science ®Google Scholar
• De Silva M, Thomas DP, Hazleman BL, Wraight P. 1979. Liposomes in arthritis: a new approach. Lancet. 1:1320–1322.
   PubMed Web of Science ®Google Scholar
• Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. 2009. Development of liposomes containing ethanol for skin delivery of temoporfin: characterization and in vitro penetration studies. Colloids Surf B Biointerfaces. 74:114–122.
   PubMed Web of Science ®Google Scholar
• Dragicevic-Curic N, Winter S, Krajisnik D, Stupar M, Milic J, Graefe S, Fahr A. 2010. Stability evaluation of temoporfin-loaded liposomal gels for topical application. J Liposome Res. 20:38–48.
   PubMed Web of Science ®Google Scholar
• Eichhorn ME, Becker S, Strieth S, Werner A, Sauer B, Teifel M, et al. 2006. Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer Biol Ther. 5:89–96.
   PubMed Web of Science ®Google Scholar
• Elron-Gross I, Glucksam Y, Margalit R. 2009. Liposomal dexamethasone diclofenac combinations for local osteoarthritis treatment. Int J Pharm. 376:84–91.
   PubMed Web of Science ®Google Scholar
• Fiocchi C. 2015. Inflammatory bowel disease pathogenesis: where are we? J Gastroenterol Hepatol. 1:12–18.
   Web of Science ®Google Scholar
• Foong WC, Green KL. 1993. Treatment of antigen-induced arthritis in rabbits with liposome-entrapped methotrexate injected intraarticularly. J Pharm Pharmacol. 45:204–209.
   PubMed Web of Science ®Google Scholar
• Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. 2006. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 1758:1633–1640.
   PubMed Web of Science ®Google Scholar
• Funk M, Schulze B, Guenzi E, Michaelis U, Bohnenkamp H, Eichhorn M, Schmitt-Sody M. 2007. Cationic liposomal preparations for the treatment of rheumatoid arthritis. WO/2007/134819; PCT/EP2007/004467.
   Google Scholar
• Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. 1996. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer. 74:1749–1756.
   PubMed Web of Science ®Google Scholar
• Harigai T, Hagiwara H, Ogawa Y, Ishizuka T, Kaneda S, Kimura J. 2007. Prednisolone phosphate-containing TRX-20 liposomes inhibit cytokine and chemokine production in human fibroblast-like synovial cells: a novel approach to rheumatoid arthritis therapy. J Pharm Pharmacol. 59:137–143.
   PubMed Web of Science ®Google Scholar
• Iancu L, Shneur A, Cohen H. 1979. Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 159:55–61.
   PubMedGoogle Scholar
• Immordino ML, Dosio F, Cattel L. 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 1:297–315.
   PubMed Web of Science ®Google Scholar
• Jiang L, Li L, He X, Yi Q, He B, Cao J, Pan W, Gu Z. 2015. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondrial targeting and pH-response. Biomaterials. 52:126–139.
   PubMed Web of Science ®Google Scholar
• Jubeh TT, Antler S, Haupt S, Barenholz Y, Rubinstein A. 2005. Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Mol Pharm. 2:2–11.
   PubMed Web of Science ®Google Scholar
• Jubeh TT, Barenholz Y, Rubinstein A. 2004. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res. 21:447–453.
   PubMed Web of Science ®Google Scholar
• Jubeh TT, Nadler-Milbauer M, Barenholz Y, Rubinstein A. 2006. Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J Drug Target 14:155–163.
   PubMed Web of Science ®Google Scholar
• Kaasgaard T, Andresen TL. 2010. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Deliv. 7:225–243.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Zhou SY, Niemiec S, Lee JW, Zimmermann EM, Fleisher D. 2005. Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model. Pharm Res. 22:1320–1330.
   PubMed Web of Science ®Google Scholar
• Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C, et al. 2006. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum. 54:1867–1877.
   PubMed Web of Science ®Google Scholar
• Kilfoyle BE, Sheihet L, Zhang Z, Laohoo M, Kohn J, Michniak-Kohn BB. 2012. Development of paclitaxel-TyroSpheres for topical skin treatment. J Control Release. 163:18–24.
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. 1977. Sterically stabilized Anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 36:66–75.
   Web of Science ®Google Scholar
• Lian T, Ho R. 2001. Trends and developments in liposome drug delivery systems. J Pharm Sci. 90:667–680.
   PubMed Web of Science ®Google Scholar
• Liu GX, Fang GQ, Xu W. 2014. Dual targeting biomimetic liposomes for paclitaxel/DNA combination cancer treatment. Int J Mol Sci. 15:15287–15303.
   PubMed Web of Science ®Google Scholar
• Lopez-Garcia F, Vazquez-Auton JM, Gil F, Latoore R, Moreno F, Villalaín J, Gómez-Fernández JC. 1993. Intra-articular therapy of experimental arthritis with a derivative of triamcinolone acetonide incorporated in liposomes. J Pharm Pharmacol. 45:576–578.
   PubMed Web of Science ®Google Scholar
• Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. 2004. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anticancer antibody. J Control Release. 100:135–144.
   PubMed Web of Science ®Google Scholar
• Madni A, Sarfraz M, Rehman M, Ahmad M, Akhtar N, Ahmad S, et al. 2014. Liposomal drug delivery: a versatile platform for challenging clinical applications. J Pharm Pharm Sci. 17:401–426.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 65:271–284.
   PubMed Web of Science ®Google Scholar
• Maeda P. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 41:189–207.
   PubMedGoogle Scholar
• Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, Boerman OC, Storm G. 2003. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 48:2059–2066.
   PubMed Web of Science ®Google Scholar
• Mornet S, Vasseur F, Grasset P, Veverka P, Goglio G, Demourgues A. 2006. Magnetic nanoparticle design for medical applications. J Prog Solid State Chem. 34:237–247.
   Web of Science ®Google Scholar
• Nakamura K, Abu Lila AS, Matsunaga M, Doi Y, Ishida T, Kiwada H. 2011. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther. 19:2040–2047.
   PubMed Web of Science ®Google Scholar
• Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. 2014. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 32:32–45.
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Thomas AL, Sharma RA, DeCatris M, Shields F, Beare S, Steward WP. 2002. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer. 87:15–20.
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:3159–3167.
   PubMed Web of Science ®Google Scholar
• Pople PV, Singh KK. 2011. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus. Eur J Pharm Biopharm. 79:82–94.
   PubMed Web of Science ®Google Scholar
• Rahman M, Ahmad MZ, Kazmi I, Akhter S, Afzal M, Gupta G, et al. 2012a. Advancement in multifunctional nanoparticles for the effective treatment of cancer. Expert Opin Drug Deliv. 9:367–381.
   PubMed Web of Science ®Google Scholar
• Rahman M, Ahmad MZ, Kazmi I, Akhter S, Afzal M, Gupta G, Sinha VR. 2012b. Emergence of nanomedicine as cancer targeted magic bullets: recent development and need to address the toxicity apprehension. Curr Drug Discov Technol. 9:319–329.
   PubMedGoogle Scholar
• Rahman M, Akhter S, Ahmad J, Ahmad MZ, Beg S, Ahmad FJ. 2015a. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. Expert Opin Drug Deliv. 12:635–652.
   PubMed Web of Science ®Google Scholar
• Rahman M, Beg S, Sharma G, Anwar F, Kumar V. 2015b. Emergence of lipid-based vesicular carriers as nanoscale pharmacotherapy in rheumatoid arthritis. Recent Pat Nanomed. 5:111–121.
   Google Scholar
• Rahman M, Zaki Ahmad M, Kazmi I, Akhter S, Beg S, Gupta G, et al. 2012c. Insight into the biomarkers as the novel anti-psoriatic drug discovery tool: a contemporary viewpoint. Curr Drug Discov Technol. 9:48–62.
   PubMedGoogle Scholar
• Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. 1999. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 141:103–107.
   PubMed Web of Science ®Google Scholar
• Salem M, Seidelin JB, Eickhardt S, Alhede M, Rogler G, Nielsen OH. 2015. Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants. Clin Exp Immunol. 179:426–434.
   PubMed Web of Science ®Google Scholar
• Sen K, Mahitosh M. 2013. Second generation liposomal cancer therapeutics: transition from laboratory to clinic. Int J Pharm. 448:28–43.
   PubMed Web of Science ®Google Scholar
• Singh D, Srivastava S, Pradhan M, Kanwar JR, Singh MR. 2015. Inflammatory bowel disease: pathogenesis, causative factors, issues, drug treatment strategies, and delivery approaches. Crit Rev Ther Drug Carrier Syst. 32:181–214.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. 1989. Studies of the HER2/neu protooncogene in human breast and ovarian cancer. Science. 244:707–712.
   PubMed Web of Science ®Google Scholar
• Srinath P, Vyas SP, Diwan PV. 2000. Preparation and pharmacodynamic evaluation of liposomes of indomethacin. Drug Dev Ind Pharm. 26:313–321.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, et al. 2008. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm. 346:143–150.
   PubMed Web of Science ®Google Scholar
• Ta T, Porter TM. 2013. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release. 169:112–125.
   PubMed Web of Science ®Google Scholar
• Touitou E, Shaco-Ezra N, Dayan N, Jushynski M, Rafaeloff R, Azoury R. 1992. Dyphylline liposomes for delivery to the skin. J Pharm Sci. 81:131–134.
   PubMed Web of Science ®Google Scholar
• Treadwell BL, Sever ED, Savage O, Copeman WS. 1964. Side-effects of long-term treatment with corticosteroids and corticotrophin. Lancet. 1:1121–1233.
   PubMed Web of Science ®Google Scholar
• Trotta M, Peira E, Debernardi FM, Gallarate M. 2002. Elastic liposomes for skin delivery of dipotassium glycyrrhizinate. Int J Pharm. 241:319–327.
   PubMed Web of Science ®Google Scholar
• Turker S, Erdogan S, Ozer Y, Bilgili H, Deveci S. 2008. Enhanced efficacy of diclofenac sodium loaded lipogelosome formulation in intra-articular treatment of rheumatoid arthritis. J Drug Targeting. 16:51–57.
   PubMed Web of Science ®Google Scholar
• Van den Hoven JM, Van Tomme SR, Metselaar JM, Nuijen B, Beijnen JH, Storm G. 2011. Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm. 8:1002–1015.
   PubMed Web of Science ®Google Scholar
• Williams AS, Jones SG, Goodfellow RM. 1999. Interleukin-1 (IL-1) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis. Br J Pharmacol. 128:234–240.
   PubMed Web of Science ®Google Scholar
• Yoo HS, Park TG. 2004. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 96:273–283.
   PubMed Web of Science ®Google Scholar
• Yuba E, Tajima N, Yoshizaki Y, Harada A, Hayashi H, Kono K. 2014. Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy. Biomaterials. 35:3091–3101.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kohler N, Zhang MQ. 2002. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials. 23:1553–1561.
   PubMed Web of Science ®Google Scholar
• Zhao YZ, Dai DD, Lu CT, Chen LJ, Lin M, Shen XT, et al. 2013. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Lett. 330:74–83.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhao WY, Ma X, Ju RJ, Li XY, Li N, et al. 2013. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials. 34:3626–3638.
   PubMed Web of Science ®Google Scholar